Corticosteroid Therapy Guidelines

Dosing and Administration

The British Journal of Dermatology recommends a dosing regimen of methylprednisolone 30-40mg IV every 6 hours for most inpatient bridging scenarios, providing adequate anti-inflammatory effect while minimizing potential side effects compared to higher doses 1
For acute severe ulcerative colitis, higher doses such as methylprednisolone 30mg every 12 hours may be required, as suggested by research published in Gut 2
For autoimmune conditions like pemphigus vulgaris, pulse therapy with 250-1000mg daily for 1-3 days may be considered for severe cases before transitioning to maintenance therapy, according to the British Journal of Dermatology 3, 4

The American Heart Association, as published in Circulation, recommends beginning oral prednisone approximately 15 minutes after the last IV dose when transitioning to oral therapy 5
The British Journal of Dermatology suggests a standard oral conversion of prednisone at a 1:1 dose ratio with methylprednisolone 1
The tapering schedule should be individualized based on the condition being treated and patient response, as recommended by the British Journal of Dermatology 4

The American Heart Association, as published in Circulation, recommends monitoring vital signs, particularly blood pressure and heart rate, during administration 5
The American Gastroenterological Association, as published in Gastroenterology, recommends regular blood glucose monitoring, especially in patients with diabetes or at risk for steroid-induced hyperglycemia 6
For pregnant patients, methylprednisolone 16mg IV every 8 hours for up to 3 days may be used for severe hyperemesis gravidarum, followed by tapering over 2 weeks, as suggested by research published in Gastroenterology 6
The European League Against Rheumatism, as published in Annals of the Rheumatic Diseases, recommends considering prophylaxis for steroid-induced osteoporosis for patients requiring prolonged therapy and early initiation of immunomodulatory agents to expedite the tapering/discontinuation of corticosteroids in autoimmune conditions 4, 7